Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

By T. Mitsudomi, S. Morita, Yasushi Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima and 11 more. The Lancet Oncology, 2010

4,044 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f0e549e24da7d6468442d6966c4769ec4d739c2c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jie Yang
2. Gad Getz
3. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. B. Chan
2. L. Sequist
3. B. Hughes

Citations in the corpus

• Advances in understanding cancer genomes through second-generation sequencing (2010, background): “For example, treatment with the inhibitors of the epidermal growth factor receptor kinase (EGFR), gefitinib and erlotinib, leads to a significant survival benefit in patients with lung cancer whose tumours carry EGFR mutations, but no benefit in patients whose tumours carry wild-type EGFR”
• Lung cancer: Biology and treatment options. (2015, background): “Three large controlled and randomized trials showed that gefitinib or erlotinib are better than platinum combination chemotherapy as first-line treatment for stage IIIB or IV lung adenocarcinomas in nonsmokers or former light smokers in East Asia [35,36,96,97].. Data from these trials demonstrated t”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Further confirmatory trials (Table 1) compared gefitinib (42,43), erlotinib (44,45) or afatinib (46,47) to chemotherapy specifically in EGFR-mutated NSCLC rather than simply by the clinical enrichment criteria of earlier studies.”
• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. (2012, result): “Furthermore, recent randomized phase III trials comparing first-line gefitinib or erlotinib with platinum-based doublet in patients with sensitive EGFR mutationsdemonstratedsignificantbenefitsofEGFR-TKIsoverchemotherapy.(18-21) These results support the use of EGFR mutations as selection criteria fo”